T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia.
Phase of Trial: Phase II
Latest Information Update: 18 May 2017
At a glance
- Drugs Allopurinol (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Levetiracetam (Primary) ; Cord blood stem cell therapy; Interleukin-2
- Indications Acute myeloid leukaemia; Graft-versus-host disease
- Focus Therapeutic Use
- 14 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 07 Nov 2011 New trial record